Castellano
Electoral Census
Electronic Office
Share
X
Facebook
Linkedin
WhatsApp
E-Mail
Copy to clipboard
INEbase
Research and development
Statistics on Biotechnology Use
Results year 2021
National Summary
Results based on Legal Unit
Results based on Legal Unit
Results by fields of operation
Business Sector Biotechnology indicators by branch of activity.
Units:
specified in variables
Select values to consult
Main variables
Values that contain
No. of companies carrying out R&D in Biotechnology
%Companies according to biotechnology used: Genetic code
%Companies according to biotechnology used: Functional units
%Companies according to biotechnology used: Cellular and tissue culturing and engineering
%Companies according to biotechnology used: Bioprocesses
%Companies according to biotechnology used: Sub-cellular organisms
%Companies according to biotechnology used: Bio-computing
%Companies according to biotechnology used: Nanobiotechnology
%Companies according to biotechnology used: Other
Companies in which biotechnology activities are: Main and/or exclusive
Companies in which biotechnology activities are: A secondary line of business
Companies in which biotechnology activities are: A tool necessary for production
%Company by field(s) of ultimate application of biotechnology use: Human Health
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture
%Company by field(s) of ultimate application of biotechnology use: Food products
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production
%Company by field(s) of ultimate application of biotechnology use: Environment
%Company by field(s) of ultimate application of biotechnology use: Industry
Personnel in R&D in biotechnology (no. of persons)
Personnel in R&D in biotechnology (no. of persons): Research personnel
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel
Personnel in R&D in biotechnology (no. of persons). Women
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel
Personnel in R&D in biotechnology (FTE)
Personnel in R&D in biotechnology (FTE): Research personnel
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel
Personnel in R&D in biotechnology (FTE). Women
Personnel in R&D in biotechnology (FTE). Women: Research personnel
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel
Internal expenditure on R&D (thousands of euros)
1) By nature of the expense: Current expenses
1.1) Remuneration to research personnel
1.2) Remuneration to technical and auxiliary personnel
1.3) Other current expenses
2) By nature of the expense: Capital expenses
2.1) Land and buildings
2.2) Equipment and instruments
2.3) Acquisition of specific R&D software
2.4) Otros productos de propiedad intelectual específicos para I+D
1.1) By origin of the funds: Own funds
1.2) By origin of the funds: From companies
1.3) By origin of the funds: Public Administration funds
1.4) By origin of the funds: From Universities
1.5) By origin of the funds: From non profit private institutions
1.6) By origin of the funds: Foreign funds
Purchase of R&D services in biotechnology (thousands of euros)
Purchase of R&D services in biotechnology (thousands of euros): In Spain
Purchase of R&D services in biotechnology (thousands of euros): Abroad
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting
% Companies with income of an international origin related to biotechnological activities
% Turnover representing income of an international origin related to biotechnological activities
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain
% Income of an international origin related with activities according to the classification: Operating source abroad
% Income of an international origin related with activities according to the classification: Other
Selected:
67
Total:
67
Branches of activity
Values that contain
Total Companies
Services
Industry and Construction
Agriculture
Selected:
1
Total:
4
Choose format of the table
Branches of activity
Main variables
.
.
.
.
.
.
.
.
.
Decimals to show:
By default
0
1
Notes
1) '.'=numeric piece of data equal to zero not resulting from rounding FTE: Full Time Equivalent
Total:
0
series
y
0
cells
Source:National Statistics Institute